Simcere Pharmaceutical Group Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Simcere Pharmaceutical Group wird ein jährliches Gewinn- und Umsatzwachstum von 23.7% bzw. 13.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 23.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.8% betragen.

Wichtige Informationen

23.8%

Wachstumsrate der Gewinne

23.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	10.7%
Wachstumsrate der Einnahmen	13.7%
Zukünftige Eigenkapitalrendite	15.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	02 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

May 01

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Dec 29

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Aug 28

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Jun 03

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Apr 06

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Jan 10

With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case

Aug 16

Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18

Jun 27

Simcere Pharmaceutical Group Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Mar 27

Should You Be Adding Simcere Pharmaceutical Group (HKG:2096) To Your Watchlist Today?

Mar 21

Gewinn- und Umsatzwachstumsprognosen

SEHK:2096 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	9,967	1,516	912	1,564	5
12/31/2025	8,720	1,306	756	1,152	6
12/31/2024	7,503	1,021	751	1,375	6
12/31/2023	6,608	715	-829	151	N/A
9/30/2023	6,806	1,928	-504	369	N/A
6/30/2023	6,999	3,144	-178	588	N/A
3/31/2023	6,659	2,038	249	971	N/A
12/31/2022	6,324	931	676	1,354	N/A
9/30/2022	5,952	972	673	1,180	N/A
6/30/2022	5,579	1,013	671	1,006	N/A
3/31/2022	5,290	1,260	130	402	N/A
12/31/2021	5,000	1,507	-411	-202	N/A
9/30/2021	4,852	1,274	-481	-200	N/A
6/30/2021	4,703	1,042	-551	-198	N/A
3/31/2021	4,606	856	-404	-51	N/A
12/31/2020	4,509	670	-256	97	N/A
9/30/2020	4,528	699	-314	-6	N/A
6/30/2020	4,548	728	-371	-109	N/A
3/31/2020	4,792	866	-53	332	N/A
12/31/2019	5,037	1,004	265	773	N/A
12/31/2018	4,514	734	441	776	N/A
12/31/2017	3,868	350	647	939	N/A
9/30/2013	2,027	193	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 2096Das prognostizierte Gewinnwachstum (23.7% pro Jahr) liegt über der Sparquote (2.2%).

Ertrag vs. Markt: 2096Die Erträge des Unternehmens (23.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (12% pro Jahr).

Hohe Wachstumserträge: 2096Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 2096Die Einnahmen des Unternehmens (13.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.9% pro Jahr).

Hohe Wachstumseinnahmen: 2096Die Einnahmen des Unternehmens (13.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 2096Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.8%).

Simcere Pharmaceutical Group Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 14%

Consensus EPS estimates fall by 37%

Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023

Consensus EPS estimates fall by 35%

Consensus revenue estimates fall by 22%

Consensus revenue estimates fall by 13%

Recent updates

Co-Founder recently sold HK$1.2m worth of stock

Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024.

Upcoming dividend of CN¥0.16 per share

Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China

Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 14%

Dividend of CN¥0.16 announced

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024

Consensus EPS estimates fall by 37%

Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500

Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023

Consensus EPS estimates fall by 35%

Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration

Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration

Co-Founder recently bought HK$1.2m worth of stock

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Consensus revenue estimates fall by 22%

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Co-Founder recently sold HK$710k worth of stock

New minor risk - Insider selling

Co-Founder recently sold HK$2.3m worth of stock

Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023

Co-Founder recently bought HK$1.5m worth of stock

Upcoming dividend of CN¥0.16 per share at 2.3% yield

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Co-Founder recently sold HK$3.1m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Consensus revenue estimates fall by 13%

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Now 23% undervalued

Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director

Investor sentiment deteriorated over the past week

Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration

Now 24% undervalued

Co-Founder recently bought HK$7.9m worth of stock

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023

Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration

Now 20% undervalued

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment

Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment

Investor sentiment deteriorated over the past week

Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study

Insufficient new directors

Simcere Pharmaceutical Group Limited Announces Executive Changes

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application

Investor sentiment improved over the past week

First half 2022 earnings released: EPS: CN¥0.024 (vs CN¥0.21 in 1H 2021)